<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33234023</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1553-4014</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Annual review of pathology</Title>
          <ISOAbbreviation>Annu Rev Pathol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Hippo Pathway in Liver Homeostasis and Pathophysiology.</ArticleTitle>
        <Pagination>
          <StartPage>299</StartPage>
          <EndPage>322</EndPage>
          <MedlinePgn>299-322</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1146/annurev-pathol-030420-105050</ELocationID>
        <Abstract>
          <AbstractText>Studies of the regenerative capacity of the liver have converged on the Hippo pathway, a serine/threonine kinase cascade discovered in <i>Drosophila</i> and conserved from unicellular organisms to mammals. Genetic studies of mouse and rat livers have revealed that the Hippo pathway is a key regulator of liver size, regeneration, development, metabolism, and homeostasis and that perturbations in the Hippo pathway can lead to the development of common liver diseases, such as fatty liver disease and liver cancer. In turn, pharmacological targeting of the Hippo pathway may be utilized to boost regeneration and to prevent the development and progression of liver diseases. We review current insights provided by the Hippo pathway into liver pathophysiology. Furthermore, we present a path forward for future studies to understand how newly identified components of the Hippo pathway may control liver physiology and how the Hippo pathway is regulated in the liver.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Driskill</LastName>
            <ForeName>Jordan H</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA; email: Jordan.Driskill@UTSouthwestern.edu, Duojia.Pan@UTSouthwestern.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medical Scientist Training Program, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Duojia</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA; email: Jordan.Driskill@UTSouthwestern.edu, Duojia.Pan@UTSouthwestern.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 EY015708</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Annu Rev Pathol</MedlineTA>
        <NlmUniqueID>101275111</NlmUniqueID>
        <ISSNLinking>1553-4006</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090683" MajorTopicYN="N">Hippo Signaling Pathway</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008115" MajorTopicYN="N">Liver Regeneration</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Hippo pathway</Keyword>
        <Keyword MajorTopicYN="Y">YAP/TAZ</Keyword>
        <Keyword MajorTopicYN="Y">fatty liver disease</Keyword>
        <Keyword MajorTopicYN="Y">liver cancer</Keyword>
        <Keyword MajorTopicYN="Y">metabolism</Keyword>
        <Keyword MajorTopicYN="Y">regeneration</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>25</Day>
          <Hour>5</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33234023</ArticleId>
        <ArticleId IdType="mid">NIHMS1747101</ArticleId>
        <ArticleId IdType="pmc">PMC8594752</ArticleId>
        <ArticleId IdType="doi">10.1146/annurev-pathol-030420-105050</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Schuppan D, Afdhal NH. 2008. Liver cirrhosis. Lancet
371:838–51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2271178</ArticleId>
            <ArticleId IdType="pubmed">18328931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mokdad AA, Lopez AD, Shahraz S, Lozano R,Mokdad AH, et al.
2014. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 12:145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4169640</ArticleId>
            <ArticleId IdType="pubmed">25242656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michalopoulos GK, DeFrances MC. 1997. Liver regeneration. Science
276:60–66</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9082986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins GM, Anderson RM. 1931. Experimental pathology of liver: restoration of liver in the white rat following partial surgical removal. Arch. Pathol
12:186–202</Citation>
        </Reference>
        <Reference>
          <Citation>Emre S, Umman V. 2011. Split liver transplantation: an overview. Transplant. Proc
43:884–87</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21486620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Starzl TE, Fung J, Tzakis A, Todo S, Demetris AJ, et al.
1993. Baboon-to-human liver transplantation. Lancet
341:65–71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2962592</ArticleId>
            <ArticleId IdType="pubmed">8093402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawasaki S,Makuuchi M, Ishizone S,Matsunami H, Terada M, Kawarazaki H. 1992. Liver regeneration in recipients and donors after transplantation. Lancet
339:580–81</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1347095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong J, Feldmann G, Huang J, Wu S, Zhang N, et al.
2007. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell
130:1120–33</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2666353</ArticleId>
            <ArticleId IdType="pubmed">17889654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan D
2010. The Hippo signaling pathway in development and cancer. Dev. Cell
19:491–505</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3124840</ArticleId>
            <ArticleId IdType="pubmed">20951342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Machado MV, Michelotti GA, Pereira TA, Xie G, Premont R, et al.
2015. Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. J. Hepatol
63:962–70</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4575842</ArticleId>
            <ArticleId IdType="pubmed">26070409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ. 1995. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 9:534–46</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7698644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu T, Wang W, Zhang S, Stewart RA, Yu W. 1995. Identifying tumor suppressors in genetic mosaics: The Drosophila lats gene encodes a putative protein kinase. Development
121:1053–63</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7743921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kango-Singh M, Nolo R, Tao C, Verstreken P, Hiesinger PR, et al.
2002. Shar-pei mediates cell proliferation arrest during imaginal disc growth in Drosophila. Development
129:5719–30</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12421711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, et al.
2002. Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell
110:467–78</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12202036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai Z-C, Wei X, Shimizu T, Ramos E, Rohrbaugh M, et al.
2005. Control of cell proliferation and apoptosis by Mob as tumor suppressor, Mats. Cell
120:675–85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15766530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harvey KF, Pfleger CM, Hariharan IK. 2003. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell
114:457–67</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12941274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia J, Zhang W, Wang B, Trinko R,Jiang J. 2003. The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev. 17:2514–19</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC218145</ArticleId>
            <ArticleId IdType="pubmed">14561774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantalacci S, Tapon N, Líopold P. 2003. The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat. Cell Biol
5:921–27</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14502295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Udan RS, Kango-Singh M, Nolo R, Tao C, Halder G. 2003. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat. Cell Biol
5:914–20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14502294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu S, Huang J, Dong J, Pan D. 2003. hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell
114:445–56</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12941273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J, Wu S, Barrera J, Matthews K, Pan D. 2005. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell
122:421–34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16096061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Ren F, Zhang Q, Chen Y, Wang B, Jiang J. 2008. The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. Dev. Cell
14:377–87</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2292673</ArticleId>
            <ArticleId IdType="pubmed">18258485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu S, Liu Y, Zheng Y, Dong J, Pan D. 2008. The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev. Cell
14:388–98</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18258486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei Q-Y, Zhang H, Zhao B, Zha Z-Y, Bai F, et al.
2008. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol. Cell. Biol
28:2426–36</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2268418</ArticleId>
            <ArticleId IdType="pubmed">18227151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Wei X, Li W, Udan RS, Yang Q, et al.
2007. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21:2747–61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2045129</ArticleId>
            <ArticleId IdType="pubmed">17974916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Y, Pan D. 2019. The Hippo signaling pathway in development and disease. Dev. Cell
50:264–82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6748048</ArticleId>
            <ArticleId IdType="pubmed">31386861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C-Y, Zha Z-Y, Zhou X, Zhang H, Huang W, et al.
2010. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFβ-TrCP E3 ligase. J. Biol. Chem
285:37159–69</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2988322</ArticleId>
            <ArticleId IdType="pubmed">20858893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Li L, Tumaneng K, Wang C-Y, Guan K-L. 2010. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFβ-TrCP. Genes Dev. 24:72–85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2802193</ArticleId>
            <ArticleId IdType="pubmed">20048001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Ye X, Yu J, Li L, Li W, et al.
2008. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22:1962–71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2492741</ArticleId>
            <ArticleId IdType="pubmed">18579750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, et al.
2015. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat. Cell Biol
17:1218–27</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6186417</ArticleId>
            <ArticleId IdType="pubmed">26258633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galli GG, Carrara M, Yuan WC, Valdes-Quezada C, Gurung B, et al.
2015. YAP drives growth by controlling transcriptional pause release from dynamic enhancers. Mol. Cell
60:328–37</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4624327</ArticleId>
            <ArticleId IdType="pubmed">26439301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitagawa M
2007. A Sveinsson’s chorioretinal atrophy-associated missense mutation in mouse Tead1 affects its interaction with the co-factors YAP and TAZ. Biochem. Biophys. Res. Commun
361:1022–26</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17689488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koontz LM, Liu-Chittenden Y, Yin F, Zheng Y, Yu J, et al.
2013. The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev. Cell
25:388–401</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3705890</ArticleId>
            <ArticleId IdType="pubmed">23725764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalamarides M, Acosta MT, Babovic-Vuksanovic D, Carpen O, Cichowski K, et al.
2012. Neurofibromatosis 2011:a report of the Children’s Tumor Foundation annual meeting. Acta Neuropathol. 123:369–80</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3282898</ArticleId>
            <ArticleId IdType="pubmed">22083253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang N, Bai H, David KK, Dong J, Zheng Y, et al.
2010. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell
19:27–38</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2925178</ArticleId>
            <ArticleId IdType="pubmed">20643348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, et al.
2006. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat. Cell Biol
8:27–36</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16341207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D. 2013. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell
154:1342–55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3835333</ArticleId>
            <ArticleId IdType="pubmed">24012335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N. 2010. Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Dev. Cell
18:300–8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2845807</ArticleId>
            <ArticleId IdType="pubmed">20159599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapoor A, Yao W, Ying H, Hua S, Liewen A, et al.
2014. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell
158:185–97</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4109295</ArticleId>
            <ArticleId IdType="pubmed">24954535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh H, Slattery M, Ma L, Crofts A, White KP, et al.
2013. Genome-wide association of Yorkie with chromatin and chromatin-remodeling complexes. Cell Rep. 3:309–18</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3633442</ArticleId>
            <ArticleId IdType="pubmed">23395637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, et al.
2011. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell
147:759–72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22078877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janse van Rensburg HJ, Azad T, Ling M, Hao Y, Snetsinger B, et al.
2018. The Hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1. Cancer Res. 78:1457–70</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29339539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Yang X. 2015.The Hippo pathway in chemotherapeutic drug resistance. Int. J. Cancer
137:2767–73</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25348697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neto-Silva RM, de Beco S, Johnston LA. 2010. Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the Drosophila homolog of Yap. Dev. Cell
19:507–20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2965774</ArticleId>
            <ArticleId IdType="pubmed">20951343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park HW, Kim YC, Yu B, Moroishi T, Mo J-S, et al.
2015.Alternative Wnt signaling activates YAP/TAZ. Cell
162:780–94</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4538707</ArticleId>
            <ArticleId IdType="pubmed">26276632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, et al.
2014. YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell
158:157–70</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24976009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yimlamai D, Christodoulou C, Galli GG,Yanger K, Pepe-Mooney B, et al.
2014. Hippo pathway activity influences liver cell fate. Cell
157:1324–38</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4136468</ArticleId>
            <ArticleId IdType="pubmed">24906150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, et al.
2007. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol
17:2054–60</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17980593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Zhang N, Xie R, Wang W, Cai J, et al.
2015. Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP. Genes Dev. 29:1285–97</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4495399</ArticleId>
            <ArticleId IdType="pubmed">26109051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi J, Lu L, Yanger K, Wang W, Sohn BH, et al.
2016. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ. Hepatology
64:1757–72</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5863546</ArticleId>
            <ArticleId IdType="pubmed">27531557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu L, Li Y, Kim SM, Bossuyt W, Liu P, et al.
2010. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. PNAS
107:1437–42</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2824398</ArticleId>
            <ArticleId IdType="pubmed">20080689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song H, Mak KK, Topol L, Yun K, Hu J, et al.
2010. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. PNAS
107:1431–36</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2824397</ArticleId>
            <ArticleId IdType="pubmed">20080598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou D, Conrad C,Xia F,Park J-S,Payer B,et al.
2009.Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell
16:425–38</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3023165</ArticleId>
            <ArticleId IdType="pubmed">19878874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee K-P, Lee J-H, Kim T-S, Kim T-H, Park H-D, et al.
2010. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. PNAS
107:8248–53</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2889558</ArticleId>
            <ArticleId IdType="pubmed">20404163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishio M, Sugimachi K, Goto H, Wang J, Morikawa T, et al.
2016. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice. PNAS
113:E71–80</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4711826</ArticleId>
            <ArticleId IdType="pubmed">26699479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hermann A, Wennmann DO, Gromnitza S, Edeling M, VanMarck V, et al.
2018.WW and C2 domain-containing proteins regulate hepatic cell differentiation and tumorigenesis through the hippo signaling pathway. Hepatology
67:1546–59</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29116649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee S-J, et al.
2012. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26:1300–5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3387657</ArticleId>
            <ArticleId IdType="pubmed">22677547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grijalva JL, Huizenga M, Mueller K, Rodriguez S, Brazzo J, et al.
2014. Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration. Am. J. Physiol. Gastrointest. Liver Physiol
307:G196–204</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24875096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu L, Finegold MJ, Johnson RL. 2018. Hippo pathway coactivators Yap and Taz are required to coordinate mammalian liver regeneration. Exp. Mol. Med
50:e423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5992983</ArticleId>
            <ArticleId IdType="pubmed">29303509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato K, Marzioni M, Meng F, Francis H, Glaser S, Alpini G. 2019. Ductular reaction in liver diseases: pathological mechanisms and translational significances. Hepatology
69:420–30</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6324973</ArticleId>
            <ArticleId IdType="pubmed">30070383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurda GT, Zhu Q, Bai H, Pan D, Schwarz KB, Anders RA. 2014. The use of Yes-associated protein expression in the diagnosis of persistent neonatal cholestatic liver disease. Hum. Pathol
45:1057–64</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4151519</ArticleId>
            <ArticleId IdType="pubmed">24746211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai H, Zhang N, Xu Y, Chen Q, Khan M, et al.
2012. Yes-associated protein regulates the hepatic response after bile duct ligation. Hepatology
56:1097–107</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3431197</ArticleId>
            <ArticleId IdType="pubmed">22886419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pepe-Mooney BJ, Dill MT, Alemany A, Ordovas-Montanes J, Matsushita Y,et al.
2019. Single-cell analysis of the liver epithelium reveals dynamic heterogeneity and an essential role for YAP in homeostasis and regeneration. Cell Stem Cell
25:23–38.e8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6814390</ArticleId>
            <ArticleId IdType="pubmed">31080134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Planas-Paz L, Sun T, Pikiolek M, Cochran NR, Bergling S, et al.
2019. YAP, but not RSPO-LGR4/5, signaling in biliary epithelial cells promotes a ductular reaction in response to liver injury. Cell Stem Cell
25:39–53.e10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31080135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mannaerts I, Leite SB, Verhulst S, Claerhout S, Eysackers N, et al.
2015. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J. Hepatol
63:679–88</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25908270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konishi T, Schuster RM, Lentsch AB. 2018. Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia-reperfusion injury. Am. J. Physiol. Gastrointest. Liver Physiol
314:G471–82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5966748</ArticleId>
            <ArticleId IdType="pubmed">29351389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swiderska-Syn M, Xie G, Michelotti GA, Jewell ML, Premont RT, et al.
2016. Hedgehog regulates yes-associated protein 1 in regenerating mouse liver. Hepatology
64:232–44</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4917408</ArticleId>
            <ArticleId IdType="pubmed">26970079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sherman MH. 2018. Stellate cells in tissue repair, inflammation, and cancer. Annu. Rev. Cell Dev. Biol
34:333–55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30028641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su T, Bondar T, Zhou X, Zhang C, He H, Medzhitov R. 2015. Two-signal requirement for growth-promoting function of Yap in hepatocytes. eLife
4:e02948</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4363878</ArticleId>
            <ArticleId IdType="pubmed">25667983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Zheng Z, Caviglia JM, Corey KE, Herfel TM, et al.
2016. Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis. Cell Metab. 24:848–62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5226184</ArticleId>
            <ArticleId IdType="pubmed">28068223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kodama T, Yi J, Newberg JY, Tien JC, Wu H, et al.
2018.Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. PNAS
115:E10417–26</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6217425</ArticleId>
            <ArticleId IdType="pubmed">30327349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plouffe SW, Lin KC, Moore JL 3rd, Tan FE, Ma S, et al.
2018. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell. J. Biol. Chem
293:11230–40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6052207</ArticleId>
            <ArticleId IdType="pubmed">29802201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagenbeek TJ, Webster JD, Kljavin NM, Chang MT, Pham T, et al.
2018. The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors. Sci. Signal
11:eaaj1757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30206136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim W, Khan SK, Liu Y, Xu R, Park O, et al.
2018. Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma. Gut
67:1692–703</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6592016</ArticleId>
            <ArticleId IdType="pubmed">28866620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee D-H, Park JO, Kim T-S, Kim S-K, Kim T-h, et al.
2016. LATS-YAP/TAZ controls lineage specification by regulating TGFβ signaling and Hnf4a expression during liver development. Nat. Commun
7:11961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4931324</ArticleId>
            <ArticleId IdType="pubmed">27358050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Freire Valls A, Schermann G, Shen Y, Moya IM, et al.
2017. YAP/TAZ orchestrate VEGF signaling during developmental angiogenesis. Dev. Cell
42:462–78.e7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28867486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azad T,Janse van Rensburg HJ, Lightbody ED, Neveu B, Champagne A, et al.
2018.ALATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat. Commun
9:1061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5849716</ArticleId>
            <ArticleId IdType="pubmed">29535383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neto F, Klaus-Bergmann A, Ong YT, Alt S, Vion A-C, et al.
2018. YAP and TAZ regulate adherens junction dynamics and endothelial cell distribution during vascular development. eLife
7:e31037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5814147</ArticleId>
            <ArticleId IdType="pubmed">29400648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Kim YH, Kim J, Park DY, Bae H, et al.
2017. YAP/TAZ regulates sprouting angiogenesis and vascular barrier maturation. J. Clin. Investig
127:3441–61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5669570</ArticleId>
            <ArticleId IdType="pubmed">28805663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakabe M, Fan J, Odaka Y, Liu N, Hassan A, et al.
2017. YAP/TAZ-CDC42 signaling regulates vascular tip cell migration. PNAS
114:10918–23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5642684</ArticleId>
            <ArticleId IdType="pubmed">28973878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun P, Zhang G, Su X,Jin C, Yu B, et al.
2019. Maintenance of primary hepatocyte functions in vitro by inhibiting mechanical tension-induced YAP activation. Cell Rep. 29:3212–22.e4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31801084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, et al.
2006. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell
125:1253–67</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3026384</ArticleId>
            <ArticleId IdType="pubmed">16814713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen S, Guo X,Yan H, Lu Y,Ji X, et al..2015. A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. Cell Res. 25:997–1012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4559818</ArticleId>
            <ArticleId IdType="pubmed">26272168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, et al.
2014. YAP activation is an early event and a potential therapeutic target in liver cancer development. J. Hepatol
61:1088–96</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25010260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, et al.
2014. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology
147:690–701</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4143445</ArticleId>
            <ArticleId IdType="pubmed">24837480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Liu P, Tao J, Wang P, Zhang Y, et al.
2019. TEA domain transcription factor 4 is the major mediator of Yes-associated protein oncogenic activity in mouse and human hepatoblastoma. Am. J. Pathol
189:1077–90</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6526503</ArticleId>
            <ArticleId IdType="pubmed">30794805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith JL, Rodríguez TC, Mou H, Kwan S-Y, Pratt H, et al.
2020. YAP1 withdrawal in hepatoblastoma drives therapeutic differentiation of tumor cells to functional hepatocyte-like cells. Hepatology. In press. 10.1002/hep.31389</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.31389</ArticleId>
            <ArticleId IdType="pmc">PMC8500588</ArticleId>
            <ArticleId IdType="pubmed">32452550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomlinson GE, Kappler R. 2012. Genetics and epigenetics of hepatoblastoma. Pediatr. Blood Cancer
59:785–92</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22807084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai J, Maitra A, Anders RA, Taketo MM, Pan D. 2015. β-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis. Genes Dev. 29:1493–506</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4526734</ArticleId>
            <ArticleId IdType="pubmed">26193883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanas MR, Sboner A, Oliveira AM, Erickson-Johnson MR, Hespelt J, et al.
2011. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci. Transl. Med
3:98ra82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21885404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Errani C, Zhang L, Sung YS, Hajdu M, Singer S, et al.
2011.Anovel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer
50:644–53</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3264678</ArticleId>
            <ArticleId IdType="pubmed">21584898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonescu CR, Le Loarer F,Mosquera JM, Sboner A, Zhang L, et al..2013. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer
52:775–84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4089994</ArticleId>
            <ArticleId IdType="pubmed">23737213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanas MR, Ma S, Jadaan FO, Ng CK, Weigelt B, et al.
2016. Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein. Oncogene
35:929–38</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4983459</ArticleId>
            <ArticleId IdType="pubmed">25961935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan W-C, Pepe-Mooney B, Galli GG, Dill MT, Huang H-T, et al.
2018. NUAK2 is a critical YAP target in liver cancer. Nat. Commun
9:4834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6240092</ArticleId>
            <ArticleId IdType="pubmed">30446657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, et al.
2016. Inactivation of Hippo pathway is significantly associated with poor prognosis in hepatocellular carcinoma. Clin. Cancer Res
22:1256–64</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5536176</ArticleId>
            <ArticleId IdType="pubmed">26459179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, Pan Q, Zhang J, Xu X, Liu X, et al..2015. Functional and clinical evidence that TAZ is a candidate oncogene in hepatocellular carcinoma. J. Cell Biochem
116:2465–75</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25650113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han S-x, Bai E, Jin G-h, He C-c, Guo X-j, et al.
2014. Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J. Immunol. Res
2014:261365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4016924</ArticleId>
            <ArticleId IdType="pubmed">24860833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim GJ, Kim H, Park YN. 2013. Increased expression of Yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma. PLOS ONE
8:e75449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3782432</ArticleId>
            <ArticleId IdType="pubmed">24086533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao H, Jiang N, Zhou B, Liu Q, Du C. 2015. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma. Cancer Sci. 106:151–59</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4399022</ArticleId>
            <ArticleId IdType="pubmed">25495189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, et al.
2009. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer
115:4576–85</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2811690</ArticleId>
            <ArticleId IdType="pubmed">19551889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, et al.
2013. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology
144:829–40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3624083</ArticleId>
            <ArticleId IdType="pubmed">23295441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang N, Zhao Z, Long J, Li H, Zhang B, et al.
2017. Molecular alterations of the NF2 gene in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncol. Rep
38:3650–58</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29130106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue R, Chen L, Zhang C, Fujita M, Li R, et al.
2019. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell
35:932–47.e8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8317046</ArticleId>
            <ArticleId IdType="pubmed">31130341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, et al.
2012. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet
44:760–64</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22634756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, et al.
2012. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet
44:694–98</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3819251</ArticleId>
            <ArticleId IdType="pubmed">22561517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang L, Azzolin L, Di Biagio D, Zanconato F, Battilana G, et al.
2018. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Nature
563:265–69</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30401838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mello SS, Valente LJ, Raj N, Seoane JA, Flowers BM, et al.
2017.A p53 super-tumor suppressor reveals a tumor suppressive p53-Ptpn14-Yap axis in pancreatic cancer. Cancer Cell
32:460–73.e6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5659188</ArticleId>
            <ArticleId IdType="pubmed">29017057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hill MA, Alexander WB, Guo B, Kato Y, Patra K, et al.
2018. Kras and Tp53 mutations cause cholangiocyte- and hepatocyte-derived cholangiocarcinoma. Cancer Res. 78:4445–51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6097629</ArticleId>
            <ArticleId IdType="pubmed">29871934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, et al.
2014. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell
158:171–84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4110062</ArticleId>
            <ArticleId IdType="pubmed">24954536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang L, Teng H, Wang Y, Liao G, Weng L, et al.
2018. SET1A-mediated mono-methylation at K342 regulates YAP activation by blocking its nuclear export and promotes tumorigenesis. Cancer Cell
34:103–18.e9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30008322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ziosi M, Baena-López LA, Grifoni D, Froldi F, Pession A, et al.
2010. dMyc functions downstream of Yorkie to promote the supercompetitive behavior of hippo pathway mutant cells. PLOS Genet. 6:e1001140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2944792</ArticleId>
            <ArticleId IdType="pubmed">20885789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moya IM, Castaldo SA, Van den Mooter L, Soheily S, Sansores-Garcia L,et al.
2019.Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice. Science
366:1029–34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31754005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. 2008. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7:11–20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18177721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Xiao ZD, Li X, Aziz KE, Gan B, et al.
2015. AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat. Cell Biol
17:490–99</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4380807</ArticleId>
            <ArticleId IdType="pubmed">25751139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng X, Han H, Liu G-P, Ma Y-X, Pan R-L, et al.
2017. LncRNA wires up Hippo and Hedgehog signaling to reprogramme glucose metabolism. EMBO J. 36:3325–35</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5686550</ArticleId>
            <ArticleId IdType="pubmed">28963395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y, Shin D-J, Pan H, Lin Z, Dreyfuss JM, et al.
2017. YAP suppresses gluconeogenic gene expression through PGC1α. Hepatology
66:2029–41</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6082140</ArticleId>
            <ArticleId IdType="pubmed">28714135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong SH, Kim HB, Kim MC, Lee JM, Lee J-H, et al.
2018. Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer. J. Clin. Investig
128:1010–25</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5824861</ArticleId>
            <ArticleId IdType="pubmed">29400692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aylon Y, Gershoni A, Rotkopf R, Biton IE, Porat Z, et al.
2016. The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. Genes Dev. 30:786–97</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4826395</ArticleId>
            <ArticleId IdType="pubmed">27013235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng C, Zhang Y, Gao Y, Tao W, Zhang H, et al.
2016. Mst1 regulates hepatic lipid metabolism by inhibiting Sirt1 ubiquitination in mice. Biochem. Biophys. Res. Commun
471:444–49</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26903296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox AG, Hwang KL, Brown KK, Evason K, Beltz S, et al.
2016. Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat. Cell Biol
18:886–96</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4990146</ArticleId>
            <ArticleId IdType="pubmed">27428308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P, Calvisi DF, Kiss A, Cigliano A, Schaff Z, et al.
2017. Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development. Oncotarget
8:73433–47</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5650273</ArticleId>
            <ArticleId IdType="pubmed">29088718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hensley CT, Wasti AT, DeBerardinis RJ. 2013. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Investig
123:3678–84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3754270</ArticleId>
            <ArticleId IdType="pubmed">23999442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du K, Hyun J, Premont RT, Choi SS, Michelotti GA, et al.
2018. Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells. Gastroenterology
154:1465–79.e13</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5880682</ArticleId>
            <ArticleId IdType="pubmed">29305935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang C-S, Stampouloglou E, Kingston NM, Zhang L, Monti S, Varelas X. 2018. Glutamine-utilizing transaminases are a metabolic vulnerability of TAZ/YAP-activated cancer cells. EMBO Rep. 19:e43577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5989844</ArticleId>
            <ArticleId IdType="pubmed">29661856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeRan M, Yang J, Shen CH, Peters EC, Fitamant J, et al.
2014. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep. 9:495–503</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4223634</ArticleId>
            <ArticleId IdType="pubmed">25373897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, et al.
2015. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J. 34:1349–70</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4491996</ArticleId>
            <ArticleId IdType="pubmed">25796446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mo J-S, Meng Z, Kim YC, Park HW, Hansen CG, et al.
2015. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat. Cell Biol
17:500–10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4380774</ArticleId>
            <ArticleId IdType="pubmed">25751140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Qiao Y, Wu Q, Chen Y, Zou S, et al.
2017. The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. Nat. Commun
8:15280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5424161</ArticleId>
            <ArticleId IdType="pubmed">28474680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng C, Zhu Y, Zhang W, Liao Q, Chen Y, et al.
2017. Regulation of the Hippo-YAP pathway by glucose sensor O-GlcNAcylation. Mol. Cell
68:591–604.e5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29100056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koo JH, Guan K-L. 2018. Interplay between YAP/TAZ and metabolism. Cell Metab. 28:196–206</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30089241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, et al.
2014. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol
16:357–66</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24658687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Wu Y, Wang H, Zhang Y, Mei L, et al.
2014. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. PNAS
111:E89–98</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3890879</ArticleId>
            <ArticleId IdType="pubmed">24367099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mi W, Lin Q, Childress C, Sudol M, Robishaw J, et al.
2015. Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration. Oncogene
34:3095–106</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25109332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo J, Yu F-X. 2019. GPCR-Hippo signaling in cancer. Cells
8:426</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6563442</ArticleId>
            <ArticleId IdType="pubmed">31072060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F-X, Zhao B, Panupinthu N, Jewell JL, Lian I, et al.
2012. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell
150:780–91</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3433174</ArticleId>
            <ArticleId IdType="pubmed">22863277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP,Molinolo AA, et al.
2014. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated Rho GTPase signaling circuitry
Cancer Cell
25:831–45</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4074519</ArticleId>
            <ArticleId IdType="pubmed">24882515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F-X, Luo J, Mo J-S, Liu G, Kim YC, et al.
2014. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell
25:822–30</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4075337</ArticleId>
            <ArticleId IdType="pubmed">24882516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Li Q, Dang K, Ma S, Cotton JL, et al.
2019. YAP/TAZ activation drives uveal melanoma initiation and progression. Cell Rep. 29:3200–11.e4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7871510</ArticleId>
            <ArticleId IdType="pubmed">31801083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saikawa S, Kaji K, Nishimura N, Seki K, Sato S, et al.
2018. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein. Cancer Lett. 434:120–29</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30031758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng JC, Wang EY, Yi Y, Thakur A, Tsai SH, Hoodless PA. 2018. S1P stimulates proliferation by upregulating CTGF expression through S1PR2-mediated YAP activation. Mol. Cancer Res
16:1543–55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29903770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu G, Wang Y, Li W, Cao Y, Xu J, et al.
2018. COX-2 forms regulatory loop with YAP to promote proliferation and tumorigenesis of hepatocellular carcinoma cells. Neoplasia
20:324–34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5909490</ArticleId>
            <ArticleId IdType="pubmed">29505957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F-X, Zhang Y, Park HW, Jewell JL, Chen Q, et al.
2013. Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes Dev. 27:1223–32</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3690396</ArticleId>
            <ArticleId IdType="pubmed">23752589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anakk S, Bhosale M, Schmidt VA, Johnson RL, Finegold MJ, Moore DD. 2013. Bile acids activate YAP to promote liver carcinogenesis. Cell Rep. 5:1060–69</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3961013</ArticleId>
            <ArticleId IdType="pubmed">24268772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji S, Liu Q, Zhang S, Chen Q, Wang C, et al.
2019. FGF15 activates Hippo signaling to suppress bile acid metabolism and liver tumorigenesis. Dev. Cell
48:460–74.e9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30745141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naugler WE, Tarlow BD, Fedorov LM, Taylor M, Pelz C,et al.
2015. Fibroblast growth factor signaling controls liver size in mice with humanized livers. Gastroenterology
149:728–40.e15</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4550566</ArticleId>
            <ArticleId IdType="pubmed">26028580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, et al.
2011. Role of YAP/TAZ in mechanotrans-duction. Nature
474:179–83</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21654799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Codelia VA, Sun G, Irvine KD. 2014. Regulation of YAP by mechanical strain through Jnk and Hippo signaling. Curr. Biol
24:2012–17</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4160395</ArticleId>
            <ArticleId IdType="pubmed">25127217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elosegui-Artola A, Andreu I, Beedle AEM, Lezamiz A, Uroz M, et al.
2017. Force triggers YAP nuclear entry by regulating transport across nuclear pores. Cell
171:1397–410.e14</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29107331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakajima H, Yamamoto K, Agarwala S, Terai K, Fukui H, et al.
2017. Flow-dependent endothelial YAP regulation contributes to vessel maintenance. Dev. Cell
40:523–36.e6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28350986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Luo J-Y, Li B, Tian XY, Chen L-J, et al.
2016. Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow. Nature
540:579–82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27926730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apte U, Gkretsi V, Bowen WC, Mars WM, Luo J-H, et al.
2009. Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase. Hepatology
50:844–51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2914599</ArticleId>
            <ArticleId IdType="pubmed">19575460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrano I, McDonald PC, Lock F, Muller WJ, Dedhar S. 2013. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat. Commun
4:2976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3905719</ArticleId>
            <ArticleId IdType="pubmed">24356468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Li N, Li X, Tran MK, Han X, Chen J. 2015. Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins. Cell Rep. 13:524–32</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4618173</ArticleId>
            <ArticleId IdType="pubmed">26456820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan F, He Z, Kong LL, Chen Q, Yuan Q, et al.
2016. Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci. Transl. Med
8:352ra108</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27535619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loforese G, Malinka T, Keogh A, Baier F, Simillion C, et al.
2017. Impaired liver regeneration in aged mice can be rescued by silencing Hippo core kinases MST1 and MST2. EMBO Mol. Med
9:46–60</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5210079</ArticleId>
            <ArticleId IdType="pubmed">27940445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiao S, Wang H, Shi Z, Dong A, Zhang W, et al.
2014. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell
25:166–80</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24525233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurppa KJ, Liu Y, To C, Zhang T, Fan M, et al.
2020. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell
37:104–22.e12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7146079</ArticleId>
            <ArticleId IdType="pubmed">31935369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boggiano JC, Vanderzalm PJ, Fehon RG. 2011. Tao-1 phosphorylates Hippo/MST kinases to regulate the Hippo-Salvador-Warts tumor suppressor pathway. Dev. Cell
21:888–95</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3217187</ArticleId>
            <ArticleId IdType="pubmed">22075147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poon CL, Lin JI, Zhang X, Harvey KF. 2011.The sterile 20-like kinase Tao-1 controls tissue growth by regulating the Salvador-Warts-Hippo pathway. Dev. Cell
21:896–906</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22075148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Y, Liu B, Wang L, Lei H, Pulgar Prieto KD, Pan D. 2017. Homeostatic control of Hpo/MST kinase activity through autophosphorylation-dependent recruitment of the STRIPAK PP2A phosphatase complex. Cell Rep. 21:3612–23</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5741103</ArticleId>
            <ArticleId IdType="pubmed">29262338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bae SJ, Ni L, Osinski A, Tomchick DR, Brautigam CA, Luo X. 2017. SAV1 promotes Hippo kinase activation through antagonizing the PP2A phosphatase STRIPAK. eLife
6:e30278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5663475</ArticleId>
            <ArticleId IdType="pubmed">29063833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Li S, Mana-Capelli S, Roth Flach RJ, Danai LV, et al.
2014. The conserved Misshapen-Warts-Yorkie pathway acts in enteroblasts to regulate intestinal stem cells in Drosophila. Dev. Cell
31:291–304</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4254555</ArticleId>
            <ArticleId IdType="pubmed">25453828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Z, Moroishi T, Mottier-Pavie V, Plouffe SW, Hansen CG, et al.
2015.MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat. Commun
6:8357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4600732</ArticleId>
            <ArticleId IdType="pubmed">26437443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Y, Wang W, Liu B, Deng H, Uster E, Pan D. 2015. Identification of Happyhour/MAP4K as alternative Hpo/Mst-like kinases in the Hippo kinase cascade. Dev. Cell
34:642–55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4589524</ArticleId>
            <ArticleId IdType="pubmed">26364751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai J, Song X, Wang W, Watnick T, Pei Y, et al.
2018. A RhoA-YAP-c-Myc signaling axis promotes the development of polycystic kidney disease. Genes Dev. 32:781–93</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6049514</ArticleId>
            <ArticleId IdType="pubmed">29891559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Li L,Wang L,Wang C-Y, Yu J, Guan K-L. 2012. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 26:54–68</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3258966</ArticleId>
            <ArticleId IdType="pubmed">22215811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim M, Kim M, Lee S, Kuninaka S, Saya H, et al.
2013.cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes. EMBO J. 32:1543–55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3671250</ArticleId>
            <ArticleId IdType="pubmed">23644383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grise F, Bidaud A, Moreau V. 2009. Rho GTPases in hepatocellular carcinoma. Biochim. Biophys. Acta Rev. Cancer
1795:137–51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19162129</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
